Besides their main mechanism of action, which consists in the disruption of the DNA repair machinery in tumor cells harboring mutations in genes involved in this process (e.g. BRCA),7 a growing body of evidence has shed light on the immunomodulatory properties of PARP inhibition. The gene discussed is PARP1; the disease is neoplasm.